EMA’s CHMP Adopts Positive Opinion for Moderna COVID-19 Vaccine Use in Adolescents

The EMA’s CHMP has adopted a positive opinion recommending marketing authorization for Moderna’s COVID-19 vaccine (Spikevax) to include adolescents 12 years of age and older.